<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269891</url>
  </required_header>
  <id_info>
    <org_study_id>14NMHB</org_study_id>
    <nct_id>NCT02269891</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women</brief_title>
  <acronym>14NMHB</acronym>
  <official_title>A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotropics Malaysia Berhad</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of an herbal combination product&#xD;
      called Nu Femme, on menopausal symptoms in peri-menopausal women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">September 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Week 12 to week 24</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Week 12 to week 24</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Baseline to weeks 3, 6, 12 and 24</time_frame>
    <description>Assessed using the Menopause Rating Scale (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopause specific quality of life</measure>
    <time_frame>Baseline to weeks 3, 6, 12 and 24</time_frame>
    <description>Assessed using the Menopause Specific Quality of Life questionnaire (MENQOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hormone concentrations</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Estradiol-17b, FSH, LH, total testosterone and free testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid Profile</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Total cholesterol, HDL-C, LDL-C and triglycerides</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone markers</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>NTX and BSALP</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood safety parameters</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>CBC, electrolytes (Na K CL), glucose, creatinine, BUN, AST, ALT, GGT, bilirubin, Ca, albumin</description>
  </other_outcome>
  <other_outcome>
    <measure>Pap smear</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Histological analysis for abnormal cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Pelvic ultrasound</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To determine changes in endometrial thickness</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Menopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Nu Femme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules taken once daily in the morning after breakfast for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nu Femme</intervention_name>
    <description>Combination product of Labisia pumila and Eurycoma longifolia extracts</description>
    <arm_group_label>Nu Femme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female of any race between the ages of 40 and 55 years (inclusive)&#xD;
&#xD;
          -  Experiencing perimenopause (irregular menstrual cycles (&gt;3 months) or cessation of&#xD;
             menstrual period for at least 3 months within the last 12 months) OR women in&#xD;
             menopause (cessation of menstrual period for at least 12 months).&#xD;
&#xD;
          -  Peri-menopausal women must have an endometrial stripe &lt; 8 mm by ultrasound at&#xD;
             screening and menopausal women must have an endometrial stripe &lt; 5 mm. Not required&#xD;
             for subjects without an intact uterus.&#xD;
&#xD;
          -  Women with an intact cervix must have a pap smear that is normal within 12 months of&#xD;
             screening.&#xD;
&#xD;
          -  Experiences menopausal transition symptoms such as hot flushes, sweating, sleep&#xD;
             disturbance, migraine, anxiety, vaginal dryness and sexual problems.&#xD;
&#xD;
          -  Minimum of 4 hot flashes per day or 28 per week&#xD;
&#xD;
          -  Total scores of Menopause Rating Scale ≥17 indicating the menopausal symptoms are&#xD;
             moderate or severe&#xD;
&#xD;
          -  TSH screening to exclude undiagnosed hyperthyroidism&#xD;
&#xD;
          -  Willingness and ability to give written informed consent and willingness and ability&#xD;
             to understand, to participate and to comply with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with a positive mammogram&#xD;
&#xD;
          -  Significant cardiac history including uncontrolled hypertension (defined as untreated&#xD;
             systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg) or&#xD;
             current diagnosis of any major diseases of the cardiovascular, hepatic, renal,&#xD;
             gastrointestinal, pulmonary or endocrine systems&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia&#xD;
&#xD;
          -  History or current diagnosis of breast cancer or breast cancer in an identical twin,&#xD;
             or any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior&#xD;
             to randomization. Subjects with other cancers in full remission more than 5 years&#xD;
             after diagnosis are acceptable with the exceptions of breast cancer or genital organ&#xD;
             cancer (e.g., cervical cancer, uterine cancer, endometrial cancer, or ovarian cancer)&#xD;
&#xD;
          -  Uncontrolled diabetes (Type I or Type II)&#xD;
&#xD;
          -  Uncontrolled and/or untreated thyroid disorder&#xD;
&#xD;
          -  History or current diagnosis of any major diseases of the cardiovascular, hepatic,&#xD;
             renal, gastrointestinal, pulmonary or endocrine systems&#xD;
&#xD;
          -  History or current diagnosis of autoimmune conditions, immunodeficiency or&#xD;
             gynaecological disease&#xD;
&#xD;
          -  Clinically significant mental depression that is not well-controlled in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Subject has undergone major surgery within the past one year prior to the&#xD;
             randomization visit, except cholecystectomy, and appendectomy&#xD;
&#xD;
          -  Subject smokes more than 15 cigarettes a day&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past year&#xD;
&#xD;
          -  Subject has demonstrated non-compliance with treatment while enrolled in other&#xD;
             experimental protocols to which the Investigator has knowledge&#xD;
&#xD;
          -  Subject has a mental disability or significant mental illness, legal incapacity or&#xD;
             limited legal capacity or any other lack of fitness, in the Investigator's opinion, to&#xD;
             preclude subject's participation in or to complete the study&#xD;
&#xD;
          -  History or findings of undiagnosed abnormal vaginal bleeding within the previous two&#xD;
             years prior to the randomization visit, including conditions that, in the&#xD;
             Investigator's opinion are likely to be the source of unpredictable vaginal bleeding&#xD;
             (i.e. leiomyoma or endometrial polyps)&#xD;
&#xD;
          -  Subject has uterine fibroids (&gt; 2cm) or endometriosis. This assessment will be based&#xD;
             on the size of the uterus of each participant and will be assessed by the Qualified&#xD;
             Investigator&#xD;
&#xD;
          -  Pregnant, breastfeeding, or planning to become pregnant during the course of the trial&#xD;
&#xD;
          -  Positive urine pregnancy test result&#xD;
&#xD;
          -  Polycystic ovary syndrome (PCOS)&#xD;
&#xD;
          -  History of abnormal Pap smear&#xD;
&#xD;
          -  Significant abnormal liver function as defined as AST and/or ALT &gt; 2 x the upper limit&#xD;
             of normal (ULN), and/or bilirubin &gt; 2 x the ULN&#xD;
&#xD;
          -  eGFR &lt;60&#xD;
&#xD;
          -  Bleeding disorders or anaemia of any etiology defined as haemoglobin ≤ 110 g/L&#xD;
&#xD;
          -  Subject has taken any of the following medications in the time periods specified prior&#xD;
             to the screening visit and during the study&#xD;
&#xD;
        Sex hormones:&#xD;
&#xD;
        Vaginal rings and vaginal creams, ointments or gels 1 week Transdermal or topical 4 weeks&#xD;
        DHEA within 24 weeks Natural supplements advertised to have hormonal effects within 4 weeks&#xD;
        Oral within 4 weeks Intrauterine progestin implants within 8 weeks Progestin implants and&#xD;
        estrogen alone injections within 12 weeks Injected progestin and estrogen or androgen&#xD;
        implants or pellets within 24 weeks&#xD;
&#xD;
        Gonadotropin-releasing hormone (GnRH) agonists within 24 weeks&#xD;
&#xD;
        Selective Estrogen Receptor Modulators (SERMs) within 4 weeks&#xD;
&#xD;
        Glucocorticoids - Chronic high dose (≥ 7.5 mg prednisone per day or equivalent) for the&#xD;
        past 12 weeks. Exceptions: Chronic low dose corticosteroid use (&lt; 7.5 mg prednisone per&#xD;
        day, or equivalent) is permitted provided the subject has been stabilized on a dose for at&#xD;
        least 12 weeks prior to randomization and maintains the current dose and dosing regimen&#xD;
        during the study. Acute topical, inhaled, or oral (e.g. dose packs) use is not exclusionary&#xD;
        and will be permitted during the course of the study.&#xD;
&#xD;
        Antidepressant and/or antianxiety medications within 4 weeks unless a chronic stable dose&#xD;
        has been maintained for greater than 12 weeks. Subject must maintain current dose and&#xD;
        dosing regimen during the study. Use of Effexor (Venlafaxine HCl) within 4 weeks is&#xD;
        exclusionary. Use of Dixarit (Clonidine HCl) within 2 weeks is exclusionary.&#xD;
&#xD;
        Thyroid or anti-epileptic medications within 12 weeks unless a chronic stable dose has been&#xD;
        maintained for greater than 12 weeks prior to randomization. Subjects must maintain current&#xD;
        dose and dosing regimen during the study&#xD;
&#xD;
        Use of Prostaglandins within 4 weeks&#xD;
&#xD;
        Other investigational study medications within 4 weeks&#xD;
&#xD;
        Current use of propranolol&#xD;
&#xD;
        Current use of an intrauterine device (IUD)&#xD;
&#xD;
        Use of natural health products, such as primrose oil, black cohosh, soy products, other&#xD;
        than vitamin and/or mineral supplements within 4 weeks&#xD;
&#xD;
          -  Known allergy or hypersensitivity to study product ingredients&#xD;
&#xD;
          -  Subjects on a weight reduction program or a medically supervised diet.&#xD;
&#xD;
          -  Unexplained weight loss or weight gain of more than 5 kg in the month prior to&#xD;
             randomization&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Crowley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Quebec</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Montreal</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Peri-menopause</keyword>
  <keyword>Nu Femme</keyword>
  <keyword>Labisia pumila</keyword>
  <keyword>Eurycoma longifolia</keyword>
  <keyword>Hot flash</keyword>
  <keyword>Joint pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

